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Chapter 4: Scores for Inflammatory Bowel Disease 
4.1 Clinical and endoscopic scoring systems in IBD 
Statement 4.1. ECCO-ESGAR Diagnostics GL (2018) 
Clinical indices are useful for standardizing disease activity. However, despite widespread 
use, no score has been validated in clinical practice [EL5]  
4.1.1 Clinical and endoscopic scoring systems in ulcerative colitis 
There are several scoring systems presently available to classify disease severity in 
ulcerative colitis (UC) within the multiple domains of disease activity, which aid objective 
assessment of disease and guide therapeutic and monitoring strategies [1,2]. Although 
somewhat limited by subjective definitions, their strength lies in the potential to monitor 
patient progress over time [1].  
The Simple Colitis Clinical Activity Index (SCCAI) [2, 3] and the Paediatric Ulcerative 
Colitis Activity Index (PUCAI) [4] are reliable and responsive scores with clear definitions for 
clinical response and remission (see Tables). SCCAI scores range between 0 and 19 points and 
include nocturnal bowel movements and faecal urgency, which affect patient quality-of-life 
(QoL) [3]. An SCCAI score <2 indicates clinical remission and a decrease of >1.5 points from 
baseline correlates with patient-defined significant improvement [5].  
The Mayo Clinic Index (Partial Mayo Clinic Index and endoscopic subscore) and 
Ulcerative Colitis Disease Activity Index (UCDAI) are a composite assessment of clinical 
symptoms (stool frequency and rectal bleeding) and endoscopic severity (Table x) [6, 7]. While 
these indices are not validated, the Mayo Clinic Index is easy to apply and has been used for 
assessing therapeutic endpoints in adult clinical trials [8]. Clinical improvement is defined as 
the reduction of baseline scores by ≥3 points and clinical remission as an overall score ≤2 (and 
no individual subscore >1) or UCDAI ≤1 [6-8]. A Partial Mayo Score (PMS) <1 indicates 
remission [1]. The PMS has been shown to correlate well with the full scoring system [9, 10]. 
The Truelove and Witts Severity Index was described in 1955 [11]. Its elements reflect 
levels of systemic toxicity and provide objective criteria for assessment of acute severe colitis, 
need for hospitalization, and corticosteroid therapy [2] (Table y). The Lichtiger Index is a 
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modification of the Truelove and Witts Index and was used in the cyclosporine trial for steroid-
refractory UC [12].  
The Pouchitis Disease Activity Index was developed to provide a standard definition 
of pouchitis, including histological subscores [13]. A Pouchitis Disease Activity Index score ≥7 
indicates acute pouchitis and remission is defined as a score ≤2 including endoscopic 
subscores ≤1 (Supplementary Tables 1 to 6). 
 
Statement 4.1.1. ECCO-ESGAR Diagnostics GL (2018) 
Endoscopic scores in ulcerative colitis (UC) should be used for standardization of care [EL5]. 
The Mayo Clinic subscore (MCS) is accepted and extensively used and the UC endoscopic 
index of severity (UCEIS) and the UC colonoscopic index of severity (UCCIS) are formally 
validated [EL2]. The Pouchitis Disease Activity Index provides a standard definition of 
pouchitis [EL4]  
Endoscopic scoring systems in ulcerative colitis  
 A plethora of UC endoscopic scoring systems has been developed over the years [1, 2, 
14, 15]. These systems are also increasingly used in clinical practice to guide treatment 
decisions with the aim of achieving mucosal healing (MH) (Table 1) [16-19]. 
The first attempt to classify endoscopic UC severity was performed by Truelove and 
Witts [11]. Mucosal appearance is classified into the following three categories: (1) normal or 
near normal, (2) improved, or (3) no change or worse. This classification lacks well-defined 
endoscopic descriptors.  
Baron et al. subsequently evaluated interobserver agreement using rigid 
sigmoidoscopy [20]. The degree of disease activity is based on a 4-point scale (0–3) mainly 
according to bleeding severity. The presence of ulceration is not taken into account. A Baron 
score ≤1 (0, normal mucosa; 1, abnormal mucosa but non-haemorrhagic) is defined as 
endoscopic remission. The Baron score has not been formally validated.  
Feagan et al. described the Modified Baron Score (MBS) in a placebo-controlled trial 
[21, 22]. Endoscopic activity is categorized according to a 5-point scale (0–4).  
The Powell-Tuck index (also known as St. Mark’s index) [23] grades the severity of 
inflammation using a 3-point scale (0–2), focusing on mucosal bleeding as the predominant 
variable.  
The Sutherland index (UC Disease Activity Index, UCDAI) [7] was developed during a 
placebo-controlled trial. Mucosal appearance is described on a 4-point scale (0–3) evaluating 
the following three endoscopic findings: (1) friability, (2) exudation, and (3) spontaneous 
haemorrhage. 
The Rachmilewitz Endoscopic Index [24] was developed during a controlled trial. The 
index includes the following four variables: (1) vascular pattern, (2) granularity, (3) mucosal 
damage (mucus, fibrin, exudate, erosions, ulcers), and (4) bleeding. The cut-off for endoscopic 
remission is ≤4 points. 
The endoscopic component of the Mayo Clinic Score (MCS) [6] assesses inflammation 
based on a 4-point scale (0–3) as follows: (0) normal, (1) erythema, decreased vascular 
pattern, mild friability, (2) marked erythema, absent vascular pattern, friability, erosions, and 
(3) ulceration, spontaneous bleeding. The MCS is most commonly used in clinical trials [8]. 
Clinical response is defined as reduction of baseline MCS scores by ≥3 points and a decrease 
of 30% from the baseline score with a decrease of at least 1 point on the rectal bleeding 
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subscale or an absolute rectal bleeding score of 0 or 1 [18]. Clinical remission is defined as an 
MCS ≤2 and no individual subscore >1. MH has been defined as a subscore of 0 to 1 [18]. 
Interobserver agreement can vary markedly [18]. For the MCS, the most inflamed part 
determines the overall score.  
The Modified Mayo Score (MMES) divides the colon into five segments and the score 
for each segment is added to give a Modified Score [25], which is multiplied by the maximal 
extent of inflammation and divided by the number of segments with active inflammation to 
give the final MMES.  
The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) is a validated endoscopic 
index that was developed due to the wide interobserver variation. UCEIS grades three 
endoscopic findings in the most severely affected part of the colon, namely vascular pattern, 
bleeding, and erosions and ulcers. Initially developed as an 11-point score, UCEIS was 
simplified to an 8-point tool scoring erosions and ulcers (0–2), vascular pattern (0–2), and 
bleeding (1–4) with a satisfactory interobserver agreement (κ 0.5) [26]. Friability has been 
excluded from this index. The extent of disease is not relevant in this score. While this score 
appears more responsive to change following treatment than the MCS, UCEIS is still not 
extensively used due to lack of familiarity [27, 28]. The remission target is a score ≤1. The 
UCEIS shows strong correlation with patient-reported outcomes [29-31]. Both UCEIS and MCS 
have demonstrated a high degree of correlation for UC (Supplementary Table 7) [32].   
The Ulcerative Colitis Colonoscopic Index of Severity (UCCIS) has recently been 
prospectively validated [33]. The UCCIS includes the following six variables: (1) vascular 
pattern, (2) granularity, (3) ulceration, (4) bleeding and friability, (5) grading of segmental and 
global assessment of endoscopic severity with a predefined 4-point scale, and (6) global 
assessment of endoscopic severity on a 10-cm visual analogue scale (VAS) scale. While the 
UCCIS has good to excellent interobserver agreement, a cut-off level for endoscopic response 
and remission is currently lacking. 
 
Supplementary Table 1. Clinical scoring system for the Simple Clinical Colitis Activity Index 
[3] 
Symptom Score 
Bowel frequency (day)  
 1–3 0 
 4–6 1 
 7–9 2 
 >9 3 
Bowel frequency (night)  
 1–3 1 
 4–6 2 
Urgency of defecation  
 Hurry 1 
Immediately 
 
2 
Incontinence 
 
3 
Blood in stool  
Trace 
 
1 
Occasionally frank 2 
 4 
Usually frank 3 
General well being 
 
 
 Very well 0 
 Slightly below par 1 
 Poor 2 
 Very poor 3 
 Terrible 4 
Extracolonic features (joints, eyes, mouth, 
skin, perianal)  
1 per 
manifestation 
 
 
Supplementary Table 2. The Powell-Tuck (St Mark’s) Index [23] 
Symptoms and signs Score 
Bowel frequency  
 3–6 1 
 >6 2 
Stool consistency  
 Formed 0 
 Semi-formed 1 
 Liquid 2 
Abdominal pain  
 Before/after bowel motions 1 
 Prolonged 2 
Anorexia 1 
Nausea/vomiting 1 
General health  
 Normal 0 
 Slightly impaired 1 
 Activities restricted 2 
 Unable to work 3 
Extracolonic manifestations  
 One/mild 1 
 More than one/severe 2 
Abdominal tenderness  
 Mild 1 
 Marked 2 
 Rebound 3 
Body temperature (°C)  
 <37.1 0 
 37.1–38 1 
 >38 2 
Blood in stool  
 Trace 1 
 More than trace 2 
Sigmoidoscopy  
 Non-haemorrhagic 0 
 Friable 1 
 Spontaneous bleed 2 
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Supplementary Table 3. Disease activity in ulcerative colitis, adapted from Truelove and 
Witts [11] 
 Mild Moderate 
‘between mild and severe’ 
Severe 
Bloody 
stools/day 
<4 4–6 ≥6 and 
Pulse <90 bpm ≤90 bpm >90 bpm or 
Temperature <37.5oC ≤37.8oC >37.8oC or 
Haemoglobin >11.5 g/dL ≥10.5 g/dL <10.5 g/dL or 
ESR <20 mm/hr ≤30 mm/hr >30 mm/hr or 
CRP Normal ≤30 mg/L >30 mg/L 
 
Supplementary Table 4. Mayo score for ulcerative colitis [6] 
Mayo index 0 1 2 3 
Stool frequency Normal 1–2/day 
>normal 
3–4/day >normal 5/day >normal 
Rectal bleeding None Streaks Obvious Mostly blood 
Mucosa Normal Mild friability Moderate friability Spontaneous bleeding 
Physician’s global 
assessment 
Normal Mild Moderate Severe 
 
 
Supplementary Table 5. Paediatric Ulcerative Colitis Activity Index [4] 
Variable Points 
 
Abdominal pain  
Absent 0 
Ignorable 5 
Not able to be ignored 10 
Rectal bleeding  
None 0 
Small amount (<50%) of stools 10 
Small amount with most stools 20 
Large amount (>50%) of stools 30 
Stool consistency  
Formed 0 
Partially formed 5 
Completely loose 10 
Number of stools in 24 hours  
0–2 0 
3–5 5 
6–8 10 
9+ 15 
 6 
Nocturnal stools  
No 0 
Yes 10 
Activity level  
No limitations 0 
Occasional limitation 
Severe restrictions 
5 
10 
 
Supplementary Table 6. Pouchitis Disease Activity Index [13] 
Variable Score 
Clinical  
Stool frequency (daily) 0–2 (usual post-operative frequency, 1–2 stools more than 
baseline, >3 stools more than baseline) 
Rectal bleeding 0–1 (absent/rare, present daily) 
Urgency 0–2 (absent, occasional, usual) 
Fever 0–1 (absent, temperature >100.5F) 
Endoscopy 1 point each (oedema, granularity, friability, decreased or absent 
vascular pattern, mucous exudates, ulceration) 
Histology 1–3 (mild, moderate, or severe polymorphonuclear leukocyte 
infiltration) 
 1–3 (<25%, 25–50%, >50% ulceration) 
Pouchitis defined as total score ≥7 points. Remission is score ≤2 with endoscopic subscore 
≤1 
 
 
Supplementary Table 7. The Ulcerative Colitis Endoscopic index of Severity [26] 
Descriptor (score 
most severe lesions) 
Likert scale anchor points Definition 
Vascular pattern Normal [0]  
Patchy 
obliteration (1) 
 
Obliterated (2)  
 
Normal vascular pattern with 
arborization of capillaries clearly 
defined, or with blurring or patchy 
loss of capillary margins 
Bleeding None (0) 
 
Mucosal (1) 
 
 
 
 
Luminal mild (2) 
 
Luminal moderate or severe (3) 
No visible blood 
 
Some spots or streaks of 
coagulated blood on the surface of 
the mucosa ahead of the scope that 
can be washed away 
 
Some free liquid blood in the lumen 
 
Frank blood in the lumen ahead of 
endoscope or visible oozing from 
mucosa after washing intraluminal 
blood, or visible oozing from a 
haemorrhagic mucosa 
Erosions and 
ulcers 
None (0) 
 
 
Erosions (1) 
 
 
 
Superficial ulcer (2) 
 
 
Normal mucosa, no visible erosions 
or ulcers 
 
Small (<5 mm) defects in the 
mucosa, of a white or yellow colour 
with a flat edge 
 
Larger (>5 mm) defects in the 
mucosa, which are discrete fibrin-
covered ulcers when compared with 
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Deep ulcer (3) 
erosions, but remain superficial 
 
Deeper excavated defects in the 
mucosa with a slightly raised edge 
 
 
Table 1. Comparison of endoscopic scoring indexes in ulcerative colitis. Adapted from 
Annese V et al. [34].  
Score Endoscopic 
variables 
Strengths Weaknesses Proposed 
Remission 
Score 
Truelove and Witts 
[11] 
Sigmoidoscopic 
assessment  
No endoscopic 
descriptor definitions 
----- ----- ----- 
Baron Score  
[20] 
Vascular pattern, 
friability, bleeding 
Easy to calculate 
 
Does not evaluate ulcers 
Subjective interpretation of 
friability and bleeding 
Poor interobserver 
agreement 
0–1 
Powell-Tuck index 
(St. Mark’s Index) 
[23] 
 
Bleeding (non-
haemorrhagic vs. 
haemorrhagic 
mucosa) 
------- 
Only evaluates bleeding 
Subjective interpretation 
Not defined 
Sutherland Index 
[7] 
 
Friability, exudation, 
spontaneous 
haemorrhage 
 
------- 
Does not evaluate ulcers 
Not accurate in 
discriminating between mild 
to moderate friability 
0 
Mayo Endoscopic 
Subscore [6] 
Erythema, vascular 
pattern, friability, 
erosions, ulcers, 
bleeding 
Easy to calculate 
Widely used in clinical trials 
Not accurate in 
discriminating between mild 
to moderate friability 
0–1 
Rachmilewitz Index 
[24] 
Vascular pattern, 
granularity, mucosal 
damage (mucus, 
fibrin, exudate, 
erosions, ulcers, 
bleeding 
Easy to calculate 
 
Subjective interpretation of 
mucosal damage and 
bleeding 
0–4 
Modified Baron 
Score [21] 
Vascular pattern, 
granularity, 
hyperaemia, 
friability, ulceration, 
bleeding 
Easy to calculate 
Used in clinical trials 
No discrimination between 
superficial and deep 
ulceration 0 
UCEIS [26] Vascular pattern, 
bleeding, 
erosions, and ulcers 
 
Accurate for the assessment 
of disease severity 
Developed following 
rigorous methodology 
Low agreement for normal 
appearance of the mucosa 
 
Validated 
UCCIS [33] Vascular pattern, 
granularity, 
ulceration, bleeding, 
and friability  
Accurate, easy scoring as 
based only on only four 
different parameters 
Developed and validated 
following rigorous 
methodology 
Covers the entire colon 
Single-centre development, 
high expertise 
 Broader validation needed 
Validated 
UCEIS, Ulcerative Colitis Endoscopic Index of Severity; UCCIS, Ulcerative Colitis Colonoscopic Index of Severity. 
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4.1.2 Clinical and endoscopic scoring systems in Crohn’s disease 
Numerous tools are available for assessing disease activity in Crohn’s disease (CD) 
patients [35]. The most commonly used clinical activity indices are the Harvey-Bradshaw 
Index (HBI), the Crohn’s Disease Activity Index (CDAI), and the Perianal Disease Activity 
Index (PDAI) (Table x) [36]. Measuring clinical activity is important but no longer sufficient, 
and both CDAI and HBI are limited by subjective interpretation (Supplementary Table 8) [37, 
38].  
The CDAI [37] was developed by Best et al. in 1976. The CDAI consists of eight factors, 
each summed after adjustment with a weighting factor. Remission is defined as CDAI <150 
and a value >450 represents severe disease. Most major research studies on medications in 
CD define response as decrease in CDAI of >70 points [39].  
The CDAI system has some limitations. These include interobserver variability; 
relevant weight for scores of ‘general wellbeing’ and ‘intensity of abdominal pain’ items, 
which are subjective and reflect patients’ perceptions of their disease; and the calculation of 
the CDAI is based on a diary completed by the patient for 7 days before evaluation. This 
requirement precludes the use of the CDAI in everyday practice. Furthermore, the CDAI is not 
accurate in patients with fistulizing or stenotic behaviour and it is not useful in patients with 
previous extensive ileocolonic resections or stoma. Currently, however, the CDAI is the most 
frequently used index for clinical trials [40]. 
The HBI was developed in 1980 as a simpler version of CDAI. The HBI consists of only clinical 
parameters; the first three items are scored from the previous day. These items include 
general well-being, abdominal pain, number of liquid stools per day, abdominal mass, and 
complications.  
The HBI relies primarily on assessment of patient symptoms with scattered use of 
objective parameters. It correlates poorly with biological evidence of active disease, including 
endoscopic assessments and C-reactive protein levels. Furthermore, the HBI has the 
limitation of overestimating disease activity in the setting of concomitant functional bowel 
symptoms while underestimating disease in a subset of patients who may have subclinical 
stricturing or penetrating luminal complications [41]. 
Patients with CD who have an HBI score ≤3 are very likely to be in remission according to the 
CDAI. Patients with a score of 8 to 9 or higher are considered to have severe disease.  
The Crohn's Disease Digestive Damage Score (the Lémann score) considers damage 
location, severity, extent, progression, and reversibility as measured by diagnostic imaging 
modalities and history of surgical resection (see chapter on cross-sectional imaging). The 
Lémann score is expected to represent a patient's disease course and to assess the effect of 
various medical therapies [42]. 
Irvine developed the PDAI [43]. Each of the five elements identified was graded on a 
5-point Likert scale. Correlation between the PDAI (maximum 20 points) and the physician 
and patient global assessment is good. A more recent scoring system proposed by Pikarsky et 
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al. [44] attempts to predict the outcome following surgical intervention in patients with 
perianal CD.  
 
 
Statement 4.1.2.  ECCO-ESGAR Diagnostics GL (2018) 
The Crohn’s disease endoscopic index of severity (CDEIS) and the simple endoscopic score 
for Crohn’s disease (SES-CD) are validated and reproducible scoring systems measuring 
luminal endoscopic activity [EL2]. There is no validated definition and score of mucosal 
healing (MH) in Crohn’s disease (CD). 
The severity of postoperative CD recurrence in the neo-terminal ileum should be stratified 
using the Rutgeerts score [EL2] 
 
There are currently three endoscopic scoring systems for CD, namely the Crohn’s 
Disease Endoscopic Index of Severity (CDEIS) [45], the Simple Endoscopic Score for Crohn’s 
Disease (SES-CD) [46], and the Rutgeerts endoscopic grading scale for post-operative 
recurrence (Table 2 and Supplementary Table 9) [34, 47].  
The CDEIS scores CD activity (from 0 to 44) in five bowel segments (terminal ileum, 
right colon, transverse, left colon and sigmoid, and rectum) and considers specific mucosal 
lesions (such as ulcers and stenosis) and extent of disease [45, 48, 49]. The CDEIS is 
complicated to use, requires training and experience in estimating the extent of ulcerated or 
diseased mucosal surfaces, and expertise in distinguishing deep from superficial ulcerations. 
The CDEIS is also time consuming. It has consequently not become routine in clinical practice 
and is used mainly in clinical trials. 
The SES-CD was developed to simplify the CDEIS. The SES-CD includes four variables, 
each considered in five bowel segments (ulcer size, extent of ulcerated surface, extent of 
affected surface, and stenosis). Scores range from 0 to 6. The SES-CD correlates highly with 
CDEIS. Defining SES-CD cut-offs must take into account endoscopically meaningful changes 
[46, 50]. However, as the SES-CD do not define MH, this score is currently not really used in 
clinical practice.  
Rutgeerts et al. developed a score for grading lesions in the neo-terminal ileum and 
anastomosis [47]. This score is considered the gold standard for establishing the prognosis in 
cases of postoperative recurrence; a score of 3 and 4 are validated cut-offs for predicting 
clinical relapse. The Modified Rutgeerts Score refers to a more refined definition of grade i2, 
which includes lesions confined to the ileocolonic anastomosis (i2a) or moderate lesions on 
the neo-terminal ileum (i2b) [51].  
4.1.3 Capsule endoscopy scores 
The Capsule Endoscopy CD Activity Index (CECDAI or Niv score) was validated in a 
multicentre prospective study of patients with isolated small-bowel CD [52]. The CECDAI 
evaluates the following three endoscopic parameters: inflammation (A, 0 to 5 points), extent 
of disease (B, 0 to 3 points), and strictures (C, 0 to 3 points), both for the proximal and distal 
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segments of the small bowel based on the transit time of the capsule (Supplementary Table 
10).  
The Lewis score assesses villous oedema, ulcers, and stenosis and classifies CD activity 
from mild to severe [53]. The small bowel is first divided into three equal parts (tertiles) based 
on capsule transit time from the first duodenal image to the first caecal image. For each 
tertile, a subscore is determined based on the extent and distribution of oedema and on the 
number, size, and distribution of ulcers. The Lewis score is the sum of the worst affected 
tertile plus the stenosis score (Supplementary Table 11).  
These small-bowel capsule endoscopy scoring systems have been developed only recently, 
and their usefulness in clinical trials and clinical practice remains to be seen [48]. 
Supplementary Table 8. Non-endoscopic Crohn's disease activity indices in clinical practice 
 Activity Index  Acronym 
Range and 
(remission) values 
Comments for clinical practice 
Clinical    
Crohn's Disease 
Activity Index [3] 
CDAI 0–600 (<150) 
Calculation based on a 7-day diary 
Difficulty in assessment of perianal 
disease activity 
Harvey-Bradshaw 
Index [38]  
HBI 0–50 (≤4) 
Simple and more practical 
Perianal Crohn's 
Disease Activity Index 
[43] 
PDAI 0–19 
Problematic fistula severity 
assessment 
 
Supplementary Table 9. The most commonly used endoscopic scores for Crohn’s disease  
Score Variables included Field of 
applicability 
Comments 
Rutgeerts score 
[47]  
 
 
 
Modified 
Rutgeerts score 
Aphthous ulcers, 
ulcers, aphthoid ileitis, 
erythema, 
cobblestone, stenosis  
 
Grade i2 lesions 
confined to ileocolonic 
anastomosis (i2a) or 
moderate lesions on 
the neo-terminal ileum 
(i2b) 
Postoperative 
recurrence (only at 
the site of ileocaecal 
anastomosis) 
 
Postoperative 
recurrence grade i2 
Widely accepted, easy 
and suitable for routine 
practice, relevant 
prognostic value 
 
No significant difference 
on the probability of 
clinical recurrence in i2a 
and i2b patients 
CDEIS [51] Ulcers and ulcerated 
areas or surfaces 
affected by disease, 
ulcerated or 
nonulcerated stenosis 
in all ileocolonic 
segments explored 
Luminal Crohn’s 
disease 
Validated and used in 
several trials, sensitive to 
variations in endoscopic 
activity. 
Complex and time-
consuming, not suitable 
for routine practice  
SES-CD [45] Ulcer size, surfaces 
affected by ulcers, 
surfaces affected by 
disease, type of bowel 
narrowing (all scored 
in all ileocolonic 
segments explored) 
Luminal Crohn’s 
disease 
Simplification of some 
CDEIS variables, results 
may be linearly derived 
into CDEIS values 
Still complex and time-
consuming 
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CDEIS, Crohn’s disease endoscopic index of severity; SES-CD, simple endoscopic score for 
Crohn’s disease 
 
Supplementary Table 8. CECDAI (Niv score) for capsule endoscopy [52] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 91. Lewis score for capsule endoscopy [53]  
 Number Extent Descriptors 
Villous appearance  
(worst-affected tertile) 
Normal – 0 ≤10% – 8 Single – 1 
Oedematous – 1 11–50% – 12 Patchy – 14 
 >50% – 20 Diffuse – 17 
Ulcer  
(worst-affected tertile) 
None – 0 ≤10% – 5 <1/4 – 9 
Single – 3 11–50% – 10 1/4–1/2 – 12 
2–7 – 5 >50% – 15 >1/2 – 18 
≥8 – 10  (percentage of the frame  
A. Inflammation score 
0 = None 
1 = Oedema/hyperaemia/denudation (mild to moderate) 
2 = Oedema/hyperaemia/denudation (severe) 
3 = Bleeding, exudate, aphthae, erosion, ulcer <0.5 cm 
4 = Ulcer 0.5–2 cm, pseudopolyp 
5 = Large ulcer >2 cm 
B. Extent of disease score 
0 = No disease 
1 = Focal disease (single segment) 
2 = Patchy disease (2–3 segments) 
3 = Diffuse disease (>3 segments) 
C. Stricture score 
0 = None 
1 = Single-passed 
2 = Multiple-passed 
3 = Obstruction (non-passage) 
 
CECDAI = proximal (A1 × B1 + C1) + distal (A2 × B2 + C2) 
 12 
 Number Extent Descriptors 
occupied by the largest ulcer)  
Stenosis  
(whole study) 
None – 0 Nonulcerated – 2 Traversed – 7 
Single – 14 Ulcerated – 24 Not traversed – 10 
Multiple – 20   
Lewis score = tertile with highest score (result of oedema and ulcers) plus score of stenosis for the entire 
small bowel 
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Table 2. Characteristics of the most commonly used scores to assess endoscopic activity in 
Crohn’s disease 
Score Applicability Variable Grading 
Rutgeerts 
score [47] 
Post-operative 
CD 
i0 No lesions in neoterminal ileum 
i1 ≤5 aphthoid ulcers 
i2  
(modified to i2a, i2b) 
>5 aphthoid ulcers with normal 
mucosa in between, skip areas with 
larger lesions, or lesions or ulcers 
(<1 cm) confined to ileocolonic 
anastomosis 
Lesions confined to the ileocolonic 
anastomosis (i2a) or moderate 
lesions on the neo-terminal ileum 
(i2b) 
i3 
Diffuse aphthous ileitis with 
extensively inflamed mucosa 
i4 
Diffuse inflammation with large 
ulcers, nodules, or stenosis (or both) 
CDEIS [51] Luminal CD 
Deep ulcers (in all 
explored segments) 
Absent (0 points) 
Present (12 points) 
Superficial ulcers (in 
all explored 
segments) 
Absent (0 points) 
Present (6 points) 
Surface disease 
involvement (in all 
explored segments) 
0–10 (result of visual-analogic scale 
transformation representing a 
complete ileocolonic segment) 
Surface ulcer 
involvement (in all 
explored segments) 
0–10 (visual-analogic scale 
transformation representing a 
complete ileocolonic segment) 
Ulcerated stenosis 
(anywhere) 
Absent (0 points) 
Present (3 points) 
Nonulcerated 
stenosis (anywhere) 
Absent (0 points) 
Present (3 points) 
SES-CD 
[45] 
Luminal CD 
Ulcers (in all explored 
segments) 
Absent (0 points) 
Aphthous ulcers, 0.1–0.5 cm (1 
point) 
Large ulcers, 0.5–2 cm (2 points) 
Very large ulcers, >2 cm (3 points) 
Ulcerated surface (in 
all explored 
segments) 
None (0 points) 
<10% of the segment (1 point) 
10–30% of the segment (2 points) 
>30% of the segment (3 points) 
Affected surface (in 
all explored 
segments) 
None (0 points) 
<50% of the segment (1 point) 
50–75% of the segment (2 points) 
>75% of the segment (3 points) 
Narrowing (in all 
explored segments) 
None (0 points) 
Single, passable by endoscope (1 
point) 
Multiple, passable by endoscope (2 
points) 
Not passable, frank stenosis (3 
points) 
CDEIS, Crohn’s disease endoscopic index of severity; SES-CD, simple endoscopic score for 
Crohn’s disease 
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4.2 Histologic scoring systems in IBD 
Statement 4.2. ECCO-ESGAR Diagnostics GL (2018) 
A validated histological score should be used in clinical practice for UC [EL3].  
There are no scores validated in clinical practice for CD [EL5] 
 
The histological examination of endoscopic biopsies is not only a crucial element in 
the diagnostic workup but also in the evaluation of therapeutic effect and in identification of 
dysplasia [2, 54, 55]. The European Society of Pathology (ESP) and the European Crohn's and 
Colitis Organisation (ECCO) published a consensus document [56, 57].  
 Since the publication of these guidelines, significant recent literature on histological 
healing and new histological scoring systems have added to our understanding of the 
assessment of disease activity, influencing the paradigms around grading and assessment of 
disease activity [58, 59].  
 
Histological remission in IBD 
In UC, histologic remission should be defined as evidence of normalization of the 
bowel mucosa. Active disease is defined by the presence of neutrophils within the crypt 
epithelium and crypt lumen (cryptitis and crypt abscesses) and ultimately by erosions and 
ulcers [56, 57]. Histologically, MH is characterized by resolution of the crypt architectural 
distortion and of the inflammatory infiltrate [60], although the mucosa may still show some 
features of sustained damage, such as a decreased crypt density with branching and 
shortening of the crypts [61]. Ultimately, basal plasmacytosis decreases, resulting in normal 
cellularity and remission may result in a complete normalization of the mucosa in 
approximately 24% of cases [62, 63]. According to ECCO-ESP, active inflammation is usually 
absent in quiescent disease. There is no consensus on the number of eosinophils acceptable, 
lymphoid aggregates, or residual basal plasmacytosis. Although endoscopic MH is associated 
with better outcomes in IBD, less is known about the significance of achieving histological 
remission [64] However, recent data suggest that histological remission, defined as minimal 
residual microscopic disease and absence of epithelial damage, is highly reproducible in 
multiple UC cohorts. Histological remitters are also more likely to achieve endoscopic and 
clinical response or remission and to remain symptom-free at 12 months after a course of 
corticosteroids. Reduced hospitalization or colectomy rates [65-68] have also been observed 
when histological remission is achieved.   
There is a need for a clear definition of ‘complete’ histological MH, or ‘histological 
remission’ and to have a reproducible, standardized, and validated histological scoring system 
for biopsy evaluation. 
A histological endpoint is likely to be more relevant in UC than CD, as the diffuse 
mucosal inflammation in UC is less subject to biopsy bias than the patchy transmural 
inflammation of CD. 
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Histological scoring systems 
 
A unique standard system for grading histologic activity does not exist [69-71]. 
Numerous methods of classification of histologic activity have been proposed and some are 
widely used, with only a few validated and proven to be reproducible. Most the published 
systems were developed for UC. Bryant et al. [64] published the results of a systematic 
bibliographic search that retrieved 22 different histological scoring systems for IBD. The most 
widely used in UC are the Riley index [72] and the Geboes [73] index. Some (such as the Riley 
index) are difficult to reproduce, as the criteria for separating grades are not provided. While 
the Geboes index is also subjective for chronic inflammation (grade 1) and eosinophils and 
neutrophils in the lamina propria (grade 2), acute inflammation is well defined. The Geboes 
index also includes the requisites to grade architecture and can be modified to include the 
evaluation of basal plasmacytosis. The recently published Nancy score [59], a three-descriptor 
histological index, has been validated for use in clinical practice and clinical trials. The 
relationship between the Nancy score and Geboes index was assessed with good 
responsiveness and correlation between them [73]. Mosli et al. recently developed an 
alternative instrument using some component items of the Geboes index (Supplementary 
Table 12) [74]. 
Few scores were designed specifically for CD. The Colonic and Ileal Global Histologic 
Disease Activity Score (CGHAS or IGHAS) is probably the most widely used. This system is 
subjective and has not been validated and its role is currently undefined (Supplementary 
Table 13).  
Practice points and future directions 
There is a clear need for a standard definition of histologic MH and for a standard and 
fully validated system of histologic disease activity.  Histology may be more effective in 
predicting clinical relapses or in evaluating benefit from therapy [37]. Meanwhile, 
pathologists should use a simple and validated scoring system to complement endoscopic 
scores. At present, the Nancy score and Robarts histopathology index are fully validated; the 
Geboes index is only partially (not formally) validated but is widely used.  
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Supplementary Table 10. Histological scoring systems in ulcerative colitis  
Author Description Comments Year of 
publication 
Truelove and 
Richards [75] 
3 grades Subjective 
Partially validated 
1956 
Matts et al. [76] 5-grade scale: (1) normal to (5) 
ulceration, erosion, 
or necrosis of the mucosa 
Not validated 1961 
Watts et al. [77] 4-grade scale: (0) normal to (3) 
severe inflammatory changes 
Not validated 1966 
Korelitz et al. [78] Mucosal cell counting in addition to 
histologic features 
Not validated 
 
1976 
Powell-Tuck et al. [79] 3-grade scale: (1) no inflammation 
(2) mild inflammation (3) moderate-
to-severe inflammation 
Not validated 
 
1982 
Keren et al. [80] Dichotomized: active versus 
inactive inflammation 
Not validated 
 
1984 
Friedman et al. [81] 4-grade scale:  
(0) normal (1) lamina propria 
inflammation (2) crypt injury (3) 
ulceration 
Not validated 
 
1986 
Gomes et al. [82] 5-grade scale: 
(0) normal to (4) severe 
inflammation and active ulceration 
Not validated 
 
1986 
Saverymuttu et al. [83] 4 histological features:  
(1) enterocyte damage 
(2) crypt abnormalities 
(3) lamina propria involvement 
(4) acute inflammatory infiltrate in 
the lamina propria.  
Each graded from (0) normal to (3) 
severe. 
Not validated 
 
1986 
Florén et al. [84] Inflammatory response graded on a 
scale of 1–5 
 
Not validated 1987 
Riley et al. [72] 6 features graded 0–4 Simple but 
subjective grading 
system 
Reproducible 
Partially validated 
1991 
Hanauer S et al. [85] 4-point categoric scale Used in the context 
of a trial, subjective 
1993 
Sandborn et al. [86] 4-grade scale:  
(0) inactive chronic colitis to 
(3) severely active chronic colitis 
Not validated 1993 
Hanauer SB et al. [87] Scores active and chronic 
inflammation and crypt distortion; 
total score derived from the sum of 
the 3 
Used in the context 
of a trial 
1998 
Geboes et al. [73] 6-grade classification 
system for inflammation, with 
subgrades 
Reproducible 
grading system 
2000 
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Partially (not 
formally) validated 
Rutter et al. [19] 5-grade scale:  
(0) normal to (4) severe active 
inflammation 
Not validated 2004 
Rubin et al. [66] 6-grade scale:  
(0) normal to (6) crypt abscesses 
in >50% of crypts or presence of 
erosion or ulceration 
Not validated 2007 
Gupta et al. [88] Harpaz score, 4-grade scale: (0) no 
cryptitis, (1) cryptitis <50% crypts, 
(2) cryptitis >50% crypts, or (4) 
ulcerations or erosions 
Partially validated 2007 
Nancy score [59] 5-level classification ranging from 
grade 0 (absence of significant 
histological disease activity) to 
grade 4 (severely active disease) 
Correlation between 
the Nancy index and 
the Geboes index is 
very good  
Validated for use in 
clinical practice 
No predictive value 
data on outcomes in 
ulcerative colitis 
2015 
Robarts 
histopathology index 
Mosli et al. [74] 
Based on Geboes index and 
modified Riley index 
Robarts is a new 
validated 
histopathological 
index (compared 
with endoscopic and 
quality-of-life 
indices) with 
favourable operating 
properties 
No predictive value 
data on outcomes in 
ulcerative colitis 
2017 
 
 
Supplementary Table 13. Histological scoring systems in Crohn’s disease 
 
Author Description Comments Year of 
publication 
D'Haens et al [89] Developed for Crohn’s Disease 
16-point grading system 
8 histological and distribution 
features 
Subjective 
Not validated 
1998 
Baars et al. [90] 4-grade scale:  
(0) no active disease to (4) severe 
inflammation (numerous crypt 
abscesses) 
Not validated 2012 
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4.3 Cross-sectional imaging scoring systems in IBD 
Statement 4.3. ECCO-ESGAR Diagnostics GL (2018)  
MR enterography-based indexes have high accuracy for assessing luminal CD activity and 
can be used in clinical trials for measuring activity and response to pharmacological 
interventions [EL3]. There are no validated scores for grading luminal activity based on 
ultrasound and CT enterography. 
Scoring of perianal fistula activity by MRI in CD allows evaluation of disease severity and 
changes after therapy [EL3] 
 
Cross-sectional imaging has an established role in clinical practice for evaluation of the 
small and large bowel in patients with CD [91]. Assessments based on cross-sectional imaging 
may have use in clinical trials with the added potential for validated indices as surrogates for 
therapeutic response. 
Cross-sectional index for luminal Crohn’s disease 
There are no formally validated indexes on luminal activity based on ultrasonography 
or CT enterography. Among the different indexes published based on MR enterography, only 
a few have been derived using valid external reference standards (i.e. endoscopy or histology) 
and use descriptors identified in multivariate analyses as independent predictors for 
detecting activity and severity (Table 3) [92].  
 
The Magnetic Resonance Index of Activity (MaRIA) is a composite index that takes 
into account bowel wall thickness, quantifies bowel enhancement after gadolinium injection, 
and identifies ulceration and bowel oedema. A subscore is calculated for five colonic 
segments and for the terminal ileum. The global score is computed as the sum total of the 
subscores. The MaRIA score has good correlation with CDEIS (r=0.83) [93, 94]. A MaRIA 
subscore of ≥7 is indicative of bowel segments with active CD and a subscore of ≥11 units 
identifies segments with severe activity (ulcers at endoscopy).  
In a study by Takenaka et al., single-balloon enteroscopy was compared with MR 
enterography in patients with ileal CD [95]. The MaRIA score closely correlated with the SES-
CD in the small bowel (r=0.808; P<0.001). A MaRIA score of ≥11 had high sensitivity, 
specificity, and diagnostic accuracy for ulcerative lesions (sensitivity, 78.3%; specificity, 
98.0%). Similarly, a MaRIA score of ≥7 had high sensitivity, specificity, and diagnostic accuracy 
for all mucosal lesions (sensitivity, 87.0%; specificity, 86.0%). 
The main limitation of the MaRIA index is that it was developed using both oral 
contrast and active colonic distension with water enema. It is still uncertain if diagnostic 
accuracy will remain similar without colonic distension [93]. MaRIA showed high accuracy for 
detecting ulcer healing (accuracy 0.9) and MH (accuracy 0.83) in CD patients following medical 
therapeutic intervention [96, 97] . 
 
The Acute Inflammation Score (AIS) is another MR enterography index and is a 
composite of two descriptors (mural thickness and mural T2 signal) that are evaluated in a 
semiquantitative fashion. A cut-off of 4.1 units defines the presence of active disease with an 
AUC of 0.77 and demonstrated a moderate degree of correlation with histopathological 
inflammation (Kendall’s tau=0.40) [98].  
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Comparative studies using ileocolonoscopy as the reference standard have validated 
both indices [99, 100]. Reproducibility is critical to be considered as a useful instrument in 
practice. Specifically, moderate-to-good degrees of interobserver agreement (0.42–0.69) 
among expert readers has been reported (Supplementary Table 14) [99].  
 
A recent index very similar to MaRIA but using diffusion-weighted imaging (DWI) 
sequence instead of contrast enhancement has been recently developed. This index is called 
the DWI-MaRIA score or Clermont score [101]. To derive and validate the DWI-MaRIA score, 
the same MR enterography (MaRIA) was considered as the reference standard [102]. The 
correlation between the MaRIA and Clermont score in the terminal ileum was almost perfect 
(r=0.99) but was significantly lower in the colon [103].   
 
The Sailer index was developed specifically for assessing postoperative recurrence at 
the anastomotic site using MR enteroclysis [104, 105].  
 
The most frequently used MRI index for perianal disease is the Van Assche index 
[106]. This score combines both the anatomical and complexity of fistula characteristics 
together with MRI findings linked to the inflammation observed. Changes in the Van Assche 
index have good correlation with clinical response to treatment [106-108]. This index has only 
been partially validated [109, 110]. However, certain aspects of the index need to be 
elucidated further, such as the responsiveness of each individual item of the index and the 
definition of a clinically relevant change in score [111].  
Bowel damage index 
The real potential for acute and chronic inflammation to cause bowel destruction 
through fibrosis and penetrating disease led the development of scoring systems for bowel 
damage [112]. The Lémann index was designed to measure damage severity in all segments 
of the digestive tract based on the assessment of stricturing and penetrating lesions using MR 
or CT and endoscopy together with previous surgery (Table 4). After an initial study [113], 
further studies demonstrated that up to 60% of patients had a reduction in score 1 year after 
starting anti-TNF therapy [114-116].  
 
In conclusion, there are different available indices for grading luminal disease using 
MR enterography. MaRIA is the best-characterized among these indices. For perianal disease, 
there is need for an improved validated index for measuring response that overcomes the 
current limitations.  
 
 
Table 3. Comparison of different MR enterography scoring systems 
 Derived Validated Responsiveness Reproducibility Strengths Limitations 
MaRIA 
index 
[103, 117] 
Ileocolono
scopy 
Ileocolonosco
py 
Yes 
(ileocolonoscopy) 
Yes Categorical 
classification in 
inactive, active, 
severe 
Time consuming 
 
AIS [118] Histopatho
logy 
Ileo 
colonoscopy 
No Yes Simplicity No definition of severe 
lesions 
DWI-
MaRIA 
Clermont 
[101] 
MR 
enterogra
phy  
(MaRIA) 
MR 
enterography  
(MaRIA) 
No No Categorical 
classification in 
inactive, active, 
severe 
Controversial applicability of 
DWI sequence in large 
multicentre trials 
MaRIA, Magnetic Resonance Index of Activity; AIS, Acute Inflammation Score; DWI-MaRIA, diffusion-weighted imaging MaRIA 
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Supplementary Table 11. Validation of MaRIA Score 
 
Context of 
Use/Characterization 
Publication Comments/Evidence 
MR enterography and 
definition of score and 
patient selection 
Rimola et al. 2009 
[103] 
Derivation of the MaRIA score highly 
correlated with CDEIS and endoscopy 
Rimola et al. 2011 
[117] 
                                            
Verification of MaRIA correlation with                                                      
endoscopy in an independent cohort 
Takenaka et al. 2015 
[95]  
 
High concordance between MaRIA and 
SES-CD; MaRIA accurate at detecting 
inflammatory activity in small bowel 
proximal to terminal ileum                                                                             
Therapeutic response 
assessment 
Ordas et al. 2014 [96] Concordance between MR enterography 
and endoscopy assessment of response to 
anti-TNF with corticosteroids 
Technical feasibility in 
multicentre setting 
Coimbra et al. 2015 
(FINCH) [93] 
Multicentre feasibility and test-retest 
Reproducibility Tielbeek et al. 2013 
[99] 
Interreader reliability 
Coimbra et al. 2015 
[93] 
Test-retest, intrareader and interreader 
reliability 
 
 
 
Supplementary Table 15. Lémann Index for the assessment of damage severity  
 
Grade Stricturing lesions  
(0–3) 
Penetrating lesions  
(0–3) 
Surgery 
Null Normal Normal Normal 
Mild Wall thickening <3 mm without  
pre-stenotic dilatation 
– - 
Moderate Wall thickening ≥3 mm without  
pre-stenotic dilatation 
Transmural fissure with increased 
density in perienteric fat 
Bypass  
strictureplasty 
Severe Stricture with 
pre-stenotic dilatation 
Abscess or fistula Resection 
For each segment, severity of damage was scored on an ordinal scale ranging from 0 (normal) to 3 
(maximal) for stricturing lesions and penetrating lesions.  
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4.4 Quality-of-life scoring systems for IBD 
Statement 4.4. ECCO-ESGAR Diagnostics GL (2018) 
The Inflammatory Bowel Diseases Questionnaire (IBDQ) is considered the gold standard 
for use in clinical trials but is lengthy and thus impractical in clinical practice [EL3]. At 
present, there is insufficient evidence to recommend a specific quality-of-life (QoL) score 
in clinical practice [EL5] 
 
Due to the wider appreciation that the nature of IBD has an often negative impact on 
patient’s lives, emphasis on health-related quality of life (HRQoL) and its assessment are 
integral to the holistic care of patients with IBD [119, 120]. QoL is now a key measure in clinical 
trials in IBD [121]. This corresponds to the WHO statement that ‘health is not merely an 
absence of disease’ but rather ‘complete physical, mental and social well-being’ [122], which 
underpins the importance of improving HRQoL as a treatment objective [123].  
HRQoL in IBD may be an indirect indicator of disease activity [124, 125] and an 
outcome measure when assessing the efficacy of treatment. There is reasonable expectation 
that effective treatment should improve QoL [126]. 
 However, QoL is just one report from patients [1] in a continuum with general QoL 
measures on one end [127], disease (IBD)-specific HRQoL measurements [128] in the centre, 
and instruments that measure specific variables likes continence [129], sexual dysfunction 
[130], food-related QoL [131], fatigue [132], and disability [133] on the other end. Some are 
specific for IBD whilst others can be used across all medical fields [121]. Disease-specific 
measures may be more sensitive to variable disease activity [134], whereas generic QoL 
instruments permit comparison of different patient populations [1, 135]. These instruments 
are not only used in adults and children alike, but the process has also been extended to 
parents [136-138], families, and carers [124]. 
The Inflammatory Bowel Diseases Questionnaire (IBDQ) is the foremost [128] and 
the most widely used tool. The IBDQ has up to 36 items and has been purported to represent 
the gold standard [139]. Short questionnaires may be more appropriate when time for 
completion is limited. In contrast, in the research setting, the need for more information may 
necessitate the use of longer questionnaires or even a combination of generic and disease-
specific questionnaires [121, 134, 135, 140]. 
Two recent systematic reviews [120, 141] analysed IBD-specific tools. Another review 
has highlighted the fragmented approach to the use of QoL in this population [135]. Some of 
the limitations are summarized in Table 4.  
The Short Health Scale (SHS) deserves a mention as it is only four questions. 
Developed in Sweden, the SHS showed good reliability, validity, and responsiveness in both 
patients with UC and CD [142, 143]. Some questions exist about its retest reliability [144]. 
English [142], Danish, and Korean versions have been also developed [143]. Additionally, the 
scale has been studied in children with IBD [145]. However, the SHS showed similar properties 
in patients with irritable bowel syndrome, thus indicating that this scale is a more generic and 
not a disease-specific instrument [146]. 
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Table 4. Difficulties and limitations of extrapolation of data and study conclusions from 
published studies to real-world IBD patients [128]  
Disease duration A shorter history of IBD might have a greater impact on HRQoL (especially 
in the first year), whereas patients with long history might have encountered 
completely different treatment and diagnostic approaches 
Disease phenotype Extent and disease location has a variable impact on HRQoL 
Gender distribution Females consistently show lower HRQoL, which creates difficulties in 
comparing results across genders 
Variability of IBDQ 
itself 
The number of questions in IBDQ can vary from 30 to 36, the Likert scales 
can have between 4 to 7 points, and either 4 or 5 dimensions have been 
described, rendering comparison of different studies invalid. 
 
The Short-Form 36 health survey (SF-36) is the generic instrument for IBD patients  
[147, 148] and is used for both clinical and research purposes [134]. The SF-36 has eight 
dimensions, which are combined into two summary scores that reflect physical and mental 
components. Individual domain scores should be reported to allow comparison across 
different nationalities [135]. 
The EQ-5D is a shorter generic tool that has also been validated in IBD [149] but is less 
frequently used. The EQ-5D has five questions or domains that have the same set of answers 
and are combined with a standardized VAS. 
As one instrument differs from another, the minimal clinically important change for 
each scale should be known (Supplementary Table 16).  
Other instruments that assess a wider range of IBD-related issues not restricted to QoL 
are listed in Supplementary Table 17.  
 
Supplementary Table 12. Suggested minimal clinically significant point changes in QoL 
measures  
 
IBDQ [150] 16–30* 
SF-36 (physical component) [151]  4.1 
SF-36 (mental component) [152] 3.9 
EQ-5D VAS [151] 9.2 
*The original publication [128] states that a change between 16 and 30 points should be considered 
a meaningful difference, whereas later a fixed value of 16 points is used as the lowest meaningful 
change [153].  
IBDQ, Inflammatory Bowel Diseases Questionnaire; SF-36, Short-Form 36 health survey; VAS, 
Visual Analogue Scale. 
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Supplementary Table 17. Other instruments not restricted to QoL  
Abbreviation Full title Characteristics 
RFIPC Rating form of IBD patient concerns [154] Measures worries and concerns of IBD – 
important psychosocial concomitants of 
the illness. With comparatively large 
number of publications [138], this 
instrument seems to have fallen out of 
favour and the last PubMed-indexed 
publication describing its use is dated 
2012 
SICC-IBD Social Impact of Chronic Conditions–
Inflammatory Bowel Disease questionnaire 
[155] 
Measures the effect of disease on 
employment, family and social 
relationships, and personal 
independence 
- The IBD disability index [156] Aims to measure the level of disability at 
social, family and work roles CPWDQ  Crohn’s Disease Perceived Work Disability 
Questionnaire [157] 
QUOTE-IBD Quality of Care Through the Patient's Eyes 
with Inflammatory Bowel Disease [158] 
A well-validated measure completed by 
patients to evaluate quality of care 
received 
CCKNOW  The Crohn's and colitis knowledge score 
[159] 
A 24-item tool to assess patient 
knowledge and understanding of their 
condition. Used and translated in 
multiple languages 
KIDSCREEN A HRQoL measure for children and 
adolescents with several variations that 
was developed simultaneously in 13 
European countries [136] 
Although not specific for IBD, it has been 
frequently used in studies on children 
and adolescents 
IMPACT-III A validated IBD-specific paediatric 
questionnaire [137] 
Translated and used in multiple countries 
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Chapter 5 General principles and technical aspects of endoscopy including enteroscopy, 
capsule endoscopy, ultrasound, CT, MRI, and SBE/SBFT 
 
5.1.1 Principles of conventional endoscopy 
 
Sedation 
 
Colonoscopy is generally perceived as unpleasant by patients. As stated by the European 
quality improvement initiative for lower gastrointestinal endoscopy, patient experience 
should be routinely measured and its improvement is crucial for acceptance [160]. 
Colonoscopy is an essential tool for diagnosing and monitoring IBD; biopsy and culture 
sampling is often needed. Although research on the development of different noninvasive 
surrogates is underway, current therapeutic goals include endoscopically assessed mucosal 
healing (MH). IBD patients undergo endoscopic procedures (mostly for surveillance) more 
often than the general population [161]. Hence, acceptance of the procedure is crucial for 
adequate management of the disease. Furthermore, endoscopy in IBD can be more 
demanding than in the general population; a prospective study on 558 colonoscopies in IBD 
patients showed a mean procedure time of 21 minutes. The current European quality 
initiative established a minimum standard of 6 minutes and a target standard mean of 10 
minutes of withdrawal time [162]. A retrospective analysis of 5282 patients who underwent 
an outpatient colonoscopy associated the prior diagnosis of IBD with higher demand of 
sedation [163, 164]. Therefore, endoscopic procedures in IBD patients should be performed 
under deep sedation instead of conscious sedation or no sedation. Propofol-based sedation 
is currently the best option for deep sedation in most cases and should be administered by 
an endoscopist, anaesthesiologist, or trained nurse according to country-specific regulation 
[164-167]. Besides deep sedation, the use of CO2 has been shown to improve patient comfort 
and satisfaction and should be implemented if possible [168].  
 
Bowel preparation 
 
Bowel preparation quality is important for the efficacy of colonoscopy and correlates with 
diagnostic yield and caecal intubation rate. Bowel preparation quality should be routinely 
measured according to validated scales [14, 160, 169]. Generally, patients with IBD do not 
have less successful bowel preparation outcomes but may have decreased preparation 
tolerance, which affects adherence. Regardless of the kind or the volume of the bowel 
preparation used, split-dose administration has demonstrated better quality and acceptance 
of the preparation in many studies. These results have been validated in two meta-analyses. 
Kilgore et al. included five trials and found that split-dose polyethylene glycol (PEG) was 
associated with satisfactory bowel cleansing and patient tolerability (odds ratio [OR] 
3.7)[170]. Martel et al. obtained similar results in an analysis of 47 trials, including split dose 
of all available preparations (OR 2.5)[171]. Hence, split-dose administration of a low-volume 
PEG-based purgative should be recommended, especially in patients with previous 
preparation intolerance, intestinal hypomotility, or stenosis [169, 172-174]. Patients who 
have undergone many colonoscopies may have a personal preference for their bowel 
preparation that should be taken into consideration [169]. IBD could be considered as a 
relative contraindication for the use of sodium phosphate-based agents, which may also 
cause mucosal abnormalities that mimic IBD [169, 174]. 
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Technical requirements and training 
 
High-definition technology is preferred over standard colonoscopy, especially when 
performing dysplasia surveillance [14, 175]. Regardless of diagnostic or therapeutic intent, 
endoscopy in IBD is technically demanding and a thorough knowledge of the disease is also 
required. Moreover, some clinical scenarios (including severely active disease or endoscopic 
dilation) appear to be associated with higher risk of perforation [14].  
 
To optimize diagnostic yield and impact of clinical management, IBD endoscopists should be 
experienced in both endoscopic and clinical management of the disease. Therefore, 
endoscopy in IBD should be considered as part of the specific training in IBD [176]. 
 
Statement 5.1.1. ECCO-ESGAR Diagnostics GL (2018) 
Conventional endoscopy is essential for diagnosis and monitoring of IBD; patient 
experience and acceptance must be considered. Propofol-based deep sedation [EL5] and 
the use of CO2 [EL5] should be offered. IBD endoscopy should be performed preferably by 
an endoscopist who is experienced in IBD endoscopy and also in IBD clinical management 
[EL5]. Bowel preparation with a split-dose polyethylene glycol (PEG)-based purgative is 
recommended [EL1] 
 
 
5.1.2 Capsule endoscopy 
 
Wireless video-capsule endoscopy is a method of endoluminal mucosal examination of the 
bowel. This form of endoscopy is based on a pill-sized camera tool that is swallowed by the 
patient and travels through the patients’ luminal digestive tract through its intrinsic motor 
activity. The capsule continuously captures images that are wirelessly transmitted to a data 
recorder worn by the patient. Images are downloaded, processed, and examined by a trained 
gastroenterologist on a workstation. 
 
Equipment 
 
All currently available small bowel video capsules are appropriate for IBD [177]. Advances in 
technology have enabled wireless capsule endoscopy systems to examine the colonic mucosa. 
Despite substantial agreement shown in different endoscopic disease activity indices 
between capsule and conventional colonoscopy, there is insufficient data to recommend 
colon capsule studies in the evaluation of IBD [177, 178]. Recently, a new capsule endoscopy 
system has been developed that evaluates both the intestinal and colonic mucosa; data 
regarding its usefulness in IBD remains however scarce [179].  
 
Patient preparation and basic technique 
 
Patients should fast for at least 12 hours prior to capsule ingestion. The use of bowel 
preparation is recommended, as this has been shown to improve the visualization and the 
 26 
diagnostic yield. Although there is not enough data to recommend any specific type of 
preparation, PEG in half dose (1 L), low volume (2 L), or high volume (4 L) has been shown to 
be beneficial [180]. As recommended for any other indication, following capsule ingestion 
with water, clear liquids may be taken after 2 hours and food and medications may be taken 
after 4 hours. 
 
Appropriate documentation of the procedure and its findings in IBD patients undergoing 
capsule endoscopy should include standardized items. Use of IBD-specific scales such as the 
Lewis score and the capsule endoscopy Crohn’s disease activity index are encouraged [53, 
180, 181]. 
 
On the basis of a recent meta-analysis, the capsule retention rate in patients with suspected 
or known IBD is approximately between 4 and 8%. These rates decreased by half in studies 
that used either a patency capsule or a cross-sectional imaging technique (such as MR 
enterography or CT enterography) to assess patency before performing capsule endoscopy 
[182].  
 
Training 
 
Capsule endoscopy should be performed by a gastroenterologist experienced in conducting, 
interpreting, and reporting capsule endoscopy procedures [180]. Moreover, capsule 
endoscopy in IBD patients should be evaluated by gastroenterologists with experience in 
conventional endoscopy in IBD patients. 
 
Statement 5.1.2. ECCO-ESGAR Diagnostics GL (2018) 
Capsule endoscopy is appropriate to evaluate small-bowel Crohn’s disease (CD). The use of 
bowel preparation [EL1] and simeticone [EL2] is recommended for capsule endoscopy 
 
 
5.1.3 Enteroscopy 
 
Equipment 
 
Enteroscopy enables live assessment, treatment, and tissue sampling of the small bowel. 
Conventional push enteroscopy is intended to access only the proximal small bowel, but the 
median insertion typically does not exceed 100 cm from the angle of Treitz [183]. In patients 
with IBD, it may be necessary to reach deeper beyond the limits of ileocolonoscopy and push 
enteroscopy. Therefore, in IBD patients undergoing direct endoscopic assessment of the small 
bowel, device-assisted enteroscopy should be performed. There is not enough data to 
recommend any modality of device-assisted deep enteroscopy, either single, double-balloon, 
spiral enteroscopy, or balloon-guided endoscopy [184]. 
 
Patient preparation and basic technique 
 
Fasting for at least 12 hours and avoidance of liquid consumption for 4 hours is generally 
sufficient for patients undergoing oral device-assisted enteroscopy. However, standard 
colonoscopy preparation is required for retrograde examination [185]. 
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Device-assisted enteroscopy is clinically challenging and requires deep sedation or general 
anaesthesia. While this procedure seems to be as safe in IBD patients as in other populations, 
the general rate of major complications is estimated at 0.7%. Accordingly, this procedure 
should only be performed if indicated and change of clinical management is intended or 
expected [184, 186]. The use of CO2 insufflation instead of room air is highly recommended 
in device-assisted enteroscopy procedures, as it may improve the intubation depth and 
reduce post-procedural discomfort [187, 188]. 
  
 
5.2. Small-bowel follow through and enteroclysis 
 
Equipment 
 
Small-bowel follow through (SBFT) and small-bowel enteroclysis (SBE) are performed using 
conventional X-ray equipment imaging. Digital fluoroscope technology is now widely available 
and allows real-time image projection and storage of image ‘loops’. Digital technology 
facilities better radiation dose control in the generally young IBD patient population. 
Equipment to compress, move, and separate the opacified small bowel should be available. 
SBFT and SBE have high accuracy for mucosal abnormalities (including ulcerations and 
strictures) and can possibly identify extramural complications, such as internal fistulae. 
 
 
Patient preparation and basic technique 
 
For both investigations, patients should be nil by mouth 6 hours prior to the procedure. SBFT 
may be augmented by pneumocolon to produce double-contrast imaging of the distal ileum, 
which enhances the sensitivity for detecting subtle mucosal changes [189]. Pneumocolon 
requires retrograde insufflation of gas (e.g. room air or CO2) into the terminal ileum via a 
rectal tube and requires bowel preparation to remove intraluminal material prior to the 
procedure [190]. 
 
SBFT consists of oral administration of 400 to 600 ml barium sulfate suspension, typically 30 
to 50% weight/volume over a specific period of time [191]. Ingested volumes should be 
individualized for each patient. This is followed by serial fluoroscopic interrogation of the 
small bowel and spot filming at intervals of 20 to 30 minutes, tracking passage of the contrast 
agent through the bowel. Targeted compression views of the small bowel are mandatory to 
ensure that the whole small bowel is visualized as far as possible. Magnified compression 
views also facilitate detailed evaluation of the small-bowel mucosa. 
 
SBE requires placement of a nasojejunal catheter under fluoroscopic guidance and insufflating 
the small bowel with barium and air or methylcellulose to create a double-contrast distended 
view of the small bowel [192, 193]. Automated pump infusion is preferred over hand 
injection. SBE in general provides better distension of the small bowel than SBFT and has been 
suggested to improve evaluation of the bowel mucosa. However, any diagnostic superiority 
over SBFT remains unproven. Furthermore, conscious sedation is sometimes necessary due 
to the discomfort the procedure can cause. 
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Technical parameters 
 
During SBE, infusion rates of should be constantly adjusted to obtain uniform distention of 
the entire small intestine without overwhelming peristaltic capacity. All accessible segments 
of the small bowel should be manually or mechanically compressed during the course of 
infusion. This includes using rotation and palpation and special manoeuvres used to isolate 
pelvic small-bowel loops [191]. Large-format images should be obtained when the entire 
small bowel is adequately filled and distended. Similarly, segments of the small bowel should 
be manually or mechanically compressed to ensure adequate visualization during SBFT.  
 
Barium sulfate is non-toxic and normally passed in stool. SBE is inherently more invasive, with 
tube placement under fluoroscopic guidance resulting in a higher radiation exposure than 
that from SBFT [194]. Although the radiation exposure for barium studies is lower than for CT, 
it is nevertheless a significant exposure for adults [195] and children [196], particularly when 
repeated examinations are performed. Moreover, excessive fluoroscopy time and frequent 
abdominal radiographs can result in doses that are equivalent to CT [196]. 
 
Training 
 
SBFT and SBE are highly operator-dependent and patient radiation doses are influenced by 
the radiologist’s technique [197, 198]. Consequently, dedicated gastrointestinal radiologists 
who are experienced in conducting and interpreting them should perform both procedures. 
 
Statement 5.2.1. ECCO-ESGAR Diagnostics GL (2018) 
Small-bowel follow through (SBFT) and small-bowel enteroclysis (SBE) have a diminishing 
role and are largely now replaced by cross-sectional techniques. However, they may have a 
role in specific clinical circumstances [EL5] 
 
 
5.3 Cross-sectional imaging techniques 
 
Reference should be made to the ESGAR/ESPR guidelines for the technical performance of 
cross-sectional small-bowel and colonic imaging [199].  
 
5.3.1 MRI and CT 
 
Equipment 
 
MR enterography and MR enteroclysis should be performed at either 1.5T or 3T. No evidence 
supports the superiority of one platform over another [200, 201]. Phased-array coils should 
be used routinely. For perianal fistula MRI, phased-array surface coils are preferred to 
endocoils, given their larger field view and greater patient acceptance [202]. Due to the 
propulsive motor action of the gut, CT requires rapid acquisition of high-resolution images of 
the bowel. Although there are no comparative studies comparing different CT platforms, CT 
enterography and CT enteroclysis in general should be performed on scanners with at least 
16 slices (ideally 64 or greater). 
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Patient preparation and basic technique 
 
Patient preparation regimens are similar to MR enterography and CT enterography. Due to 
insufficient distension of the bowel, there is evidence that studies performed without oral 
contrast preparation have inferior diagnostic accuracy when compared with those performed 
after administration of oral contrast [203, 204]. Patients should be nil by mouth for solids for 
4 to 6 hours prior to MR enterography or CT enterography. Liquids should also be restricted, 
although water is permissible. There are ranges of suitable oral agents available to distend 
the small bowel, usually with hyperosmolar properties [205]. These include mannitol, PEG, 
sorbitol, or combinations thereof [206-211]. There is currently no evidence that favours one 
preparation over another. Although use is not widespread, negative-contrast agents 
containing paramagnetic iron reduce luminal signal on both T1-weighted and T2-weighted 
images [212]. Oral contrast agents should be ingested 45 minutes prior to the examination 
[213]. Volumes over 1000 mL may give better distension [208], although it is possible to 
acquire diagnostically acceptable images with ingested volumes of 450 mL [214]. Patients 
should be warned that they might experience cramping and diarrhoea after ingesting 
hyperosmolar oral contrast agents. Enteroclysis is more invasive than enterography and is less 
well tolerated by patients [215] but may provide superior distension of the proximal small 
bowel in particular [216](59). MR enteroclysis and CT enteroclysis  should be performed with 
similar distension agents as MR enterography and CT enterography, which should be infused 
via an 8F or 10F nasojejunal tube placed under fluoroscopic guidance. Automated pump 
infusion (at a rate of 80–120 ml/min) is preferred over hand injection, although both are 
acceptable. On-table monitoring of small-bowel distension should be performed during both 
MR enteroclysis and CT enteroclysis and infused volumes should be individualized for each 
patient [199].  
 
Diagnostic accuracy for colonic inflammation is improved with colonic filling, either by 
prolonged oral contrast administration [217, 218] or via a rectal liquid enema [219]. However, 
additional colonic preparation is not required for routine MR enterography or CT 
enterography. While superior bowel distension may be achieved by placing the patient prone, 
there is no evidence that this translates into superior diagnostic accuracy over the supine 
position [220].  
 
 
Technical parameters 
 
CT images should be acquired following intravenous contrast agent administration in the 
enteric or portal venous phase only [221]. Iodinated contrast administration facilitates 
assessment of the bowel wall enhancement pattern and mesenteric vascularity. The use of 
multiplanar reformats is mandatory during CT evaluation and these should be reconstructed 
at 3 mm or less [222]. 
 
Radiation exposure is the major limiting factor for the use of CT in IBD [223, 224]. Exposure 
to high radiation doses can occur (primarily due to repeated CT) and particularly in those with 
young age of disease onset and complicated disease [225]. It is therefore imperative that dose 
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exposure is minimized by optimizing tube voltage and current [226, 227]. The use of 
automated tube current modulation reduces dose while maintaining image quality [228]. 
Furthermore, there is good data demonstrating that iterative reconstruction techniques 
significantly reduce dose while producing diagnostically acceptable images [229-233]; these 
techniques should be applied routinely when available. It is good practice to maintain a log of 
radiation exposure for patients with IBD undergoing repeat medical imaging [199]. Due to the 
risks from repeated radiation exposure given the chronic nature of the disease and need for 
repeated imaging, MRI is generally the preferred modality in IBD patients.  
 
Although diagnostically acceptable MR enterography images can be acquired without use of 
spasmolytic agents [234], administration of these agents improves bowel distension [228] and 
use is currently recommended [199]. Hyoscine butylbromide (butylscopolamine) is the 
spasmolytic agent of choice, although glucagon is an acceptable alternative [235]. High-
quality MR enterography and MR enteroclysis requires fast breath-hold sequences to 
minimize breathing and peristaltic artifacts. A typical protocol should include a combination 
of T2-weighted and steady-state free precession gradient echo (SSFP GE) sequences. T1-
weighed images acquired in the enteric or portal venous phase following intravenous 
gadolinium contrast administration facilitates assessment of the bowel wall enhancement 
pattern and mesenteric vascularity, with some evidence that it increases diagnostic accuracy 
[236, 237]. However, recent studies have reported long-term retention of gadolinium in the 
brain of exposed patients [238-241], and protocols omitting gadolinium contrast may have 
similar diagnostic accuracy [242, 243]. Administration of gadolinium should therefore be 
considered on a case-by-case basis. There is increasing data supporting the use of diffusion-
weighted imaging [243-246] and cine motility sequences [247-250] both in disease detection 
and activity assessment. Pending further research, these sequences are currently considered 
optional [199]. 
 
Sequence selection in perianal fistula imaging should include high-resolution T2-weighted 
images with and without fat saturation angled to the plane of the anal canal. Short T1 
inversion recovery (STIR) sequences are an alternative to fat-saturated T2-weighted 
sequences [251, 252]. The use of gadolinium enhancement on T1-weighted imaging is useful 
for differentiating granulation tissue from fluid, for gauging fistula activity [107], and may 
increase staging accuracy [253]. 
 
 
Training 
 
There is evidence of a learning curve in the interpretation of MR enterograpy. Initial data 
suggests that feedback on 100 cases is required to achieve diagnostic accuracy equivalent to 
experienced radiologists [254]. However, once trained, radiologists tend to maintain their 
interpretation skills long term [255]. Moderate-to-good interobserver agreement has been 
reported for MR enterography [99, 255, 256] and CT enterography [257], with one study 
suggesting higher reader agreement for CT enterography over MR enterography [258]. There 
are also data that confirmed a learning curve in the interpretation of MRI perianal fistula 
imaging, with improvement in accuracy after dedicated training [259].  
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Statement 5.3.1.1. ECCO-ESGAR Diagnostics GL (2018) 
CT enterography and CT enteroclysis should be performed on CT scanners with at least 16 
slices. MR enterography and MR enteroclysis can be performed at 1.5T or 3T [EL2] 
 
Statement 5.3.1.2. ECCO-ESGAR Diagnostics GL (2018) 
A suitable oral contrast agent should be administered 45 minutes prior to MRI and CT 
enterography or infused via nasojejunal tube prior to MR enteroclysis or CT enteroclysis 
[EL2] 
 
Statement 5.3.1.3. ECCO-ESGAR Diagnostics GL (2018) 
Dedicated colonic preparation is not part of routine protocols but can be achieved either by 
prolonged oral contrast or administration of a liquid rectal enema [EL2] 
 
Statement 5.3.1.4. ECCO-ESGAR Diagnostics GL (2018) 
Radiation exposure is a limitation of CT and should only be used if MRI or ultrasound is not 
available. Dose exposure must be minimized by optimizing acquisition parameters, use of 
tube current modulation, and iterative reconstruction techniques when available [EL2]. 
Cumulative radiation exposure of IBD patients should be monitored [EL5] 
 
Statement 5.3.1.5. ECCO-ESGAR Diagnostics GL (2018) 
MR enterography and MR enteroclysis should be performed with fast breath-hold 
sequences to minimize breathing and peristaltic artifacts [EL2]. Consideration should be 
made for the routine use of intravenous gadolinium in all patients, weighing the risks and 
benefits [EL4] 
 
Statement 5.3.1.6. ECCO-ESGAR Diagnostics GL (2018) 
Radiologists interpreting cross-sectional imaging in IBD require appropriate training, with 
initial evidence suggesting that radiologists should review at least 100 cases [EL2] 
 
 
5.3.2 Ultrasonography 
 
Equipment  
 
Modern ultrasound devices have sufficient quality and screen resolution to delineate the 
structure of the gastrointestinal wall. The resolution of an ultrasound transducer is dependent 
on the frequency, the speed of sound in tissue, and the number of cycles in the ultrasound 
pulse. Since the thickness of the bowel wall layer is usually <3 mm [260], the frequency of the 
transducer must be at least 5 MHz for wall layers to be well discriminated. No head-to-head 
studies have been published comparing the diagnostic performance of regular low-frequency, 
mid-frequency, or high-frequency probes for detection of the normal small bowel and 
pathological findings. Harmonic imaging should be activated when available, as this may 
improve delineation of the bowel wall [261]. 
 
Doppler ultrasound can assess both blood flow in the visceral vessels that supply the 
gastrointestinal tract and the smaller vessels of the intestinal wall. Doppler ultrasound cannot 
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detect capillary flow. Colour Doppler or power Doppler can both be used to evaluate bowel 
wall vascularity [262]. Flow parameters should be optimized to maximize the sensitivity for 
the detection of vessels with low-velocity flow in the bowel wall. The information obtained 
from colour Doppler images is semi-quantitative. It is recommended to measure bowel wall 
vascularity according to the number of vessels detected per square centimetre [263-265]. 
Increased vascularity of the diseased bowel wall is a marker of disease activity. To improve 
the sensitivity of Doppler ultrasound, intravenous ultrasound contrast agents have been 
introduced. For example, the second-generation echo-signal enhancer SonoVue is injected as 
a bolus in units of 1.2 to 4.5 mL into an antecubital vein, immediately followed by injection of 
10 mL of normal saline solution (0.9% NaCl) flush. For each examination, a recording is 
initiated a few seconds before the intravenous administration of the agent, and continuous 
imaging is performed for 40 seconds [266]. There are several ways of interpreting contrast 
enhancement in the bowel wall. These include pattern of enhancement [267, 268], contrast 
quantification at peak intensity [269], and dynamic contrast-enhanced ultrasound where 
intensity changes over time are analysed [270].  
 
Contrast-enhanced ultrasound 
 
Contrast-enhanced ultrasound (CEUS) can be used to quantify vascularity [271] but can also 
be used to separate vascular from avascular tissue, which is particularly useful when trying to 
differentiate a phlegmon from an abscess [272].  
 
Small intestine contrast ultrasonography  
 
In recent years, the use of oral contrast agents (such as PEG solution) has been introduced to 
distend the bowel for better characterization of the bowel wall and increased disease 
detection. The use of an oral contrast agent does not alter the procedure greatly; the same 
equipment is used with the addition of 375 to 800 mL of oral contrast fluid. However, the 
procedure duration increases, ranging from 25 to 60 minutes [273]. The accuracy for assessing 
lesions in the proximal small bowel and for defining the extent of diseased ileal walls can be 
significantly improved using small intestine contrast ultrasonography [274]. 
 
Ultrasound elastography 
 
Gut fibrosis develops in up to 50% of Crohn’s disease (CD) patients and is a major challenge 
[275]. Clinically suspected fibrostenotic disease is currently mainly investigated by contrast-
enhanced CT [276] or MR [276, 277] enterography or MR enteroclysis or native ultrasound 
and CEUS (see above). Novel MRI sequences (such as magnetization transfer) also show 
promise [278, 279], although detection and characterization of fibrotic disease by imaging 
remains suboptimal. While MR elastography is being studied for staging several diseases (such 
as liver fibrosis), it has not been studied in fibrotic bowel disease. Ultrasound elasticity 
imaging based on strain under deformation and elastic modulus [280] is an evolving 
technique. Recent studies suggest that ultrasound elastography can differentiate between 
fibrotic and inflammatory stenosis independent of wall thickness and blood flow in CD [281, 
282]. 
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Patient preparation and basic technique 
 
Abdominal ultrasound is most successful in nonobese patients due to its basic technical 
principle as discussed above. The small bowel and colon should be carefully and 
systematically interrogated, using gentle graded compression. No patient preparation is 
needed to perform bowel ultrasound. However, to reduce the amount of food and bowel gas, 
a fasting period of at least 4 to 6 hours is recommended, although there are no rigorous 
studies confirming this approach [283]. Administration of a spasmolytic agent is not required 
and indeed may interfere with the real-time assessment of bowel peristalsis by the operator. 
Colonic preparation or liquid enemas are also not required. As noted above, use of colour 
Doppler should be routine. While both CEUS and elastography are highly promising evolving 
techniques, they are not yet routinely used outside specialist centres. 
 
Training  
 
The interobserver agreement between operators with various degrees of experience in bowel 
ultrasound and its learning curve needs to be investigated further. Dedicated training in bowel 
ultrasound is necessary and should preferably be performed following training in general 
abdominal ultrasound [283, 284]. Preliminary data suggests that signs of CD in bowel 
ultrasound can be standardized and have shown fair-to-good reproducibility. In particular, 
bowel wall thickness shows excellent reproducibility [285]. 
 
Statement 5.3.2.1. ECCO-ESGAR Diagnostics GL (2018) 
For a complete examination of the bowel with ultrasound, low-resolution and high-
resolution probes should be used [EL5] 
 
 
Statement 5.3.2.2. ECCO-ESGAR Diagnostics GL (2018) 
The use of intraluminal orally administered contrast agents improves the overall accuracy 
in diagnosing small-bowel CD [EL2] 
 
Statement 5.3.2.3. ECCO-ESGAR Diagnostics GL (2018) 
Contrast-enhanced ultrasound (CEUS) of the bowel can be used to differentiate vascular 
from avascular intestinal or peri-intestinal lesions, including abscesses [EL3] 
 
Statement 5.3.2.4. ECCO-ESGAR Diagnostics GL (2018) 
A standard ultrasound examination of the intestine does not require specific patient 
preparation, although fasting is recommended before the examination [EL4] 
 
Statement 5.3.2.5. ECCO-ESGAR Diagnostics GL (2018) 
Dedicated training in bowel ultrasound is necessary and should be performed following 
training in general abdominal ultrasound [EL5] 
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